Navigation Links
Study Finds Repeated Episodes of Stent Thrombosis Common
Date:3/29/2008

Treating stent thrombosis with another stent hikes the risk of repeat blood

clotting

CHICAGO, March 29 /PRNewswire/ -- When a clot develops inside a coronary stent, it can block blood flow to the heart, potentially causing a heart attack or even death. A single incident of stent thrombosis is bad enough, but a new study suggests that one in six patients can expect to experience at least one repeat episode. According to the Dutch Stent Thrombosis Study, among the strongest predictors of recurrent stent thrombosis is implantation of an additional stent during emergency treatment of the first episode.

The study will be reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Jochem Wouter van Werkum, MD, a cardiologist at St Antonius Hospital, Nieuwegein, the Netherlands, led the study. He and his colleagues enrolled a total of 437 consecutive patients who had stent thrombosis confirmed by angiography between January 2004 and February 2007. The researchers collected data on clinical characteristics (for example, diabetes, age and duration of antiplatelet therapy), angiographic characteristics (for example, undersizing of the stent, dissection and whether the lesion was located at an arterial branchpoint), and procedural characteristics (for example, whether a drug-eluting or bare-metal stent was used and the length and diameter of the stent).

The researchers found that 74 of the 437 patients (16.9 percent) experienced multiple episodes of stent thrombosis. Of these, 61 patients had two episodes of stent thrombosis, 12 patients had three episodes and one patient had four episodes. Further analysis revealed three independent predictors of repeat stent thrombosis. Patients who had an additional stent implanted during emergency treatment for the first episode of stent thrombosis were 4.2 times as likely as other patients to experience a repeat episode of stent thrombosis (p<0.0001). Patients with a previous heart attack faced 2.6 times the usual risk of repeat stent thrombosis (p<0.001), and patients who developed thrombosis long after stent implantation (late stent thrombosis) faced 2.1 times the usual risk of a repeat episode (p=0.0127).

Dr. van Werkum and his colleagues concluded that additional stent placement at the time of emergency treatment for the first stent thrombosis should be avoided.

Dr. van Werkum will present the results of the "Dutch Stent Thrombosis Study" study on Saturday, March 29 at 8:15 a.m. CDT in the Grand Ballroom, S100.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.

About ACC

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.


'/>"/>
SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale of ... revealing the skeletons in their closets. “They Sang At Her Funeral” is the creation ... young and married with five children and twelve grandchildren. Before becoming a writer, Annalise ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... McFarland has joined its executive team as the President of its HealthBI ... care management systems and contact centers. , “Scott is a utility player ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):